We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+1.17%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$119M
AUM Growth
-$35.2M
Cap. Flow
-$21.8M
Cap. Flow %
-18.32%
Top 10 Hldgs %
65.31%
Holding
42
New
9
Increased
12
Reduced
9
Closed
9

Top Buys

Rank Stock Value
1
CRBP icon
Corbus Pharmaceuticals
CRBP
+$2.71M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$2.62M
3
BBOT
BridgeBio Oncology
BBOT
+$1.83M
4
ARGX icon
argenx
ARGX
+$1.53M
5
KURA icon
Kura Oncology
KURA
+$1.5M

Top Sells

Rank Stock Value
1
APLT
Applied Therapeutics
APLT
+$5.39M
2
IRON icon
Disc Medicine
IRON
+$4.78M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$4.71M
4
CLDX icon
Celldex Therapeutics
CLDX
+$4.57M
5
HLVX
HilleVax
HLVX
+$4.17M

Sector Composition

Rank Sector Weight
1 Healthcare 99.58%
2 Financials 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ORIC icon
26
Oric Pharmaceuticals
ORIC
$1.1B
$679K 0.57%
96,000
-7,992
-8% -$71.5K
PLRX icon
27
Pliant Therapeutics
PLRX
$64.4M
$497K 0.42%
+46,200
New +$596K
RAPP
28
Rapport Therapeutics
RAPP
$1.95B
$465K 0.39%
+20,000
New +$463K
NAMS icon
29
NewAmsterdam Pharma
NAMS
$3.21B
$432K 0.36%
+22,500
New +$451K
CYPH
30
Cypherpunk Technologies Inc
CYPH
$67.8M
$382K 0.32%
195,000
-159,166
-45% -$417K
CLRB icon
31
Cellectar Biosciences
CLRB
$21.3M
$176K 0.15%
2,350
-2,433
-51% -$233K
SVRA icon
32
PUT
Savara
SVRA
$1.09B
$101K 0.08%
+250
New +$1.11K
NUVB.WS
33
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$14.5K 0.01%
90,832
– –
APLT
34
DELISTED
Applied Therapeutics
APLT
– –
-792,000
Closed -$5.39M
CLDX icon
35
Celldex Therapeutics
CLDX
$2.96B
– –
-109,000
Closed -$4.57M
HLVX
36
DELISTED
HilleVax
HLVX
– –
-250,609
Closed -$4.17M
IMVT icon
37
Immunovant
IMVT
$7.91B
– –
-92,346
Closed -$2.98M
IRON icon
38
Disc Medicine
IRON
$2.93B
– –
-76,800
Closed -$4.78M
LYRA
39
DELISTED
LYRA THERAPEUTICS INC
LYRA
– –
-3,466
Closed -$1.08M
RARE icon
40
Ultragenyx Pharmaceutical
RARE
$2.46B
– –
-20,000
Closed -$934K
VSTM icon
41
Verastem
VSTM
$500M
– –
-207,095
Closed -$2.44M
ITCI
42
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-13,300
Closed -$920K
1
2

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q2 2024 Portfolio in Review

As of Q2 2024, Acuta Capital Partners held 42 positions worth $119M, down 23% from $154M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Acuta Capital Partners withdrew a net $21.8M in Q2 2024, closing 9 positions and reducing 9 holdings. Its most notable exit was Applied Therapeutics, an estimated $5.39M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.

Against the trend, Acuta Capital Partners opened a new position in Corbus Pharmaceuticals worth $2.92M.

  • Acuta Capital Partners's largest Q2 2024 buy was Corbus Pharmaceuticals: 64,500 shares worth $2.92M.
  • Acuta Capital Partners added most to Crinetics Pharmaceuticals in Q2 2024, an estimated $2.62M increase.
  • Acuta Capital Partners's biggest Q2 2024 reduction was Sarepta Therapeutics, cutting an estimated $4.71M.
  • Acuta Capital Partners fully exited Applied Therapeutics in Q2 2024, selling an estimated $5.39M.
  • Acuta Capital Partners's ten largest holdings make up 65% of its $119M portfolio in Q2 2024.
  • Acuta Capital Partners opened 9 new positions and closed 9 in Q2 2024.
  • Acuta Capital Partners's portfolio value fell 23% quarter-over-quarter to $119M.

Based on Acuta Capital Partners's 13F filing for Q2 2024, filed 14 Aug 2024.